Pros and cons of different therapeutic antibody formats for recombinant antivenom development.

Autor: Laustsen AH; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. Electronic address: ahola@bio.dtu.dk., María Gutiérrez J; Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica., Knudsen C; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Johansen KH; Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA., Bermúdez-Méndez E; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Cerni FA; School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil., Jürgensen JA; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Ledsgaard L; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Martos-Esteban A; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Øhlenschlæger M; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Pus U; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Andersen MR; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Lomonte B; Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica., Engmark M; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark., Pucca MB; Medical School, Federal University of Roraima, Boa Vista, Brazil.
Jazyk: angličtina
Zdroj: Toxicon : official journal of the International Society on Toxinology [Toxicon] 2018 May; Vol. 146, pp. 151-175. Date of Electronic Publication: 2018 Mar 10.
DOI: 10.1016/j.toxicon.2018.03.004
Abstrakt: Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.
(Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: